Detalhe da pesquisa
1.
Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.
J Infect Dis;
2024 Apr 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38682569
2.
Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.
J Infect Dis;
225(9): 1513-1520, 2022 05 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32658250
3.
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination.
J Infect Dis;
225(9): 1521-1532, 2022 05 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33319249
4.
Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003).
Clin Infect Dis;
75(1): 107-117, 2022 08 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34606595
5.
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
N Engl J Med;
381(21): 2009-2019, 2019 11 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31693803
6.
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
Lancet;
395(10234): 1434-1443, 2020 05 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32197107
7.
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
Lancet;
395(10234): 1423-1433, 2020 05 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32197105
8.
Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City.
Rev Panam Salud Publica;
45: e67, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34131423
9.
An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults.
J Infect Dis;
219(3): 410-414, 2019 01 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30203081
10.
Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination.
J Infect Dis;
220(4): 603-614, 2019 07 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31001633
11.
Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.
J Infect Dis;
217(4): 597-607, 2018 01 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29140444
12.
Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.
J Infect Dis;
214(6): 845-53, 2016 Sep 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27354368
13.
Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.
J Infect Dis;
211(6): 870-8, 2015 Mar 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25210140
14.
A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.
J Infect Dis;
210(11): 1763-71, 2014 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24951828
15.
Oil-in-water emulsion adjuvant with influenza vaccine in young children.
N Engl J Med;
365(15): 1406-16, 2011 Oct 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21995388
16.
Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.
PLoS Negl Trop Dis;
17(3): e0011124, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36888687
17.
Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial.
Hum Vaccin Immunother;
19(1): 2204787, 2023 12 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37140558
18.
Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
Vaccine;
41(47): 6999-7006, 2023 11 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37884415
19.
Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting.
Vaccine;
40(8): 1143-1151, 2022 02 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35078666
20.
Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study.
Vaccine;
40(26): 3588-3596, 2022 06 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35595661